Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 3 days ago

Kyverna Therapeutics, Inc.: GordonMD Global Investments LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

GordonMD Global Investments LP amended its Schedule 13G filing on Kyverna Therapeutics, Inc., updating its beneficial ownership stake in the clinical-stage cell therapy developer with the SEC under accession number 0000919574-26-008017. The filing signals a change in the investment firm's position, though the amended document's specific share count and percentage were not detailed in the headline disclosure. Kyverna, which focuses on engineered T-cell therapies for autoimmune diseases, is closely watched by biotech investors given the capital-intensive nature of its clinical programs. Stake amendments from institutional holders are typically scrutinized for signals about confidence in a company's pipeline and financing runway. Investors will look to the full 13G text for exact share totals and any indication of whether GordonMD's position was increased, reduced or left unchanged.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Kyverna Therapeutics, Inc., GordonMD Global Investments LP